Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria
暂无分享,去创建一个
H. Win | F. Nosten | Sue J Lee | N. White | M. Imwong | J. Tarning | G. Bancone | C. Turner | A. P. Phyo | Atthanee Jeeyapant | S. Proux | M. Paw | K. Sriprawat | J. Wiladphaingern | C. Chu | J. Watson | V. Carrara | W. Yotyingaphiram | Suradet Thinraow | Naw Pet Poe | Pornpimon Wilairisak | Rattanaporn Raksapraidee | A. Phyo | Jacher Wiladphaingern | Kanlaya Sriprawat
[1] H. Win,et al. Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Georgina S. Humphreys,et al. The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials , 2017, International journal for parasitology. Drugs and drug resistance.
[3] H. Win,et al. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens , 2017, PLoS medicine.
[4] I. Elyazar,et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia , 2015, BMC Medicine.
[5] S. Krudsood,et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.
[6] J. Crump,et al. Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.
[7] F. Nosten,et al. Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thai–Myanmar Border, 1999–2011: An Observational Study , 2013, PLoS medicine.
[8] Q. Bassat,et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. , 2012, The Journal of infectious diseases.
[9] R. Price,et al. Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. Baker,et al. Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. , 2011, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[11] J. Schumi,et al. TRIALS REVIEW Open Access , 2022 .
[12] J. Kaewkungwal,et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border , 2010, Malaria Journal.
[13] Joan Muela Ribera,et al. Adherence to 7-Day Primaquine Treatment for the Radical Cure of P. vivax in the Peruvian Amazon , 2010, The American journal of tropical medicine and hygiene.
[14] N. Day,et al. A Comparison of Two Short-Course Primaquine Regimens for the Treatment and Radical Cure of Plasmodium vivax Malaria in Thailand , 2010, The American journal of tropical medicine and hygiene.
[15] P. Butraporn,et al. Adherence to Antimalarial Drug Therapy among Vivax Malaria Patients in Northern Thailand , 2009, Journal of health, population, and nutrition.
[16] G. Brittenham,et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. , 2008, The American journal of tropical medicine and hygiene.
[17] R. Price,et al. Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.
[18] S. Pocock,et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.
[19] N. White,et al. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. , 2004, Acta tropica.
[20] N. Gogtay,et al. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. , 1999, Annals of tropical medicine and parasitology.
[21] N. White,et al. Treatment of vivax malaria on the western border of Thailand. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[22] N. Gogtay,et al. A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[23] J. Baird,et al. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. , 1997, The American journal of tropical medicine and hygiene.
[24] S. Pukrittayakamee,et al. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. , 1994, The Journal of infectious diseases.
[25] N. Sitaraman,et al. Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu. , 1977, The Indian journal of medical research.
[26] D. Clyde,et al. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. , 1977, The American journal of tropical medicine and hygiene.
[27] W. Collins,et al. Five day primaquine therapy--an evaluation of radical curative activity against vivax malaria infection. , 1973, The American journal of tropical medicine and hygiene.
[28] Margaret Mitchell,et al. Brief Report: Special Modifications of the Fluorescent Screening Method for Glucose-6-Phosphate Dehydrogenase Deficiency , 1968 .
[29] Douglas G. Altman,et al. Reporting of Noninferiority and Equivalence Randomized Trials , 2013 .
[30] P. Gething,et al. The global public health significance of Plasmodium vivax. , 2012, Advances in parasitology.
[31] S. Krudsood,et al. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. , 2011, The Southeast Asian journal of tropical medicine and public health.
[32] Douglas G Altman,et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.